Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)

DOMENICO GALETTA, FRANCESCO GIOTTA, GERARDO ROSATI, VITTORIO GEBBIA, LUIGI MANZIONE, MAURIZIO DI BISCEGLIE, NICOLA BORSELLINO and GIUSEPPE COLUCCI
Anticancer Research November 2005, 25 (6C) 4445-4449;
DOMENICO GALETTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: galetta@teseo.it
FRANCESCO GIOTTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERARDO ROSATI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VITTORIO GEBBIA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUIGI MANZIONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAURIZIO DI BISCEGLIE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLA BORSELLINO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPE COLUCCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited. Carboplatin (CB) is a platinum derivative with less toxicity than CDDP. Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC. Materials and Methods: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC. Thirty-two patients were enrolled and included in an intent-to-treat analysis. Toxicity was graded according to NCI criteria. Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included. Patients had to be >18 years old with ECOG PS of 0-2 and adequate bone marrow, renal and liver functions. CB (AUC 5) and R (3 mg/m2) were administered intravenously every 3 weeks. The median age was 62 years (range 43-71), 29 M/3 F. The median PS was 1 (0-2). Twelve patients were staged III and 20 were metastatic (10 recurrent). The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients. The median number of cycles delivered was 3, while globally 115 cycles were administered. The median time to progression was 4.2 months and median duration of survival was 9.8 months. Results: Seven patients achieved a partial response (22%), 10 patients showed a stable disease (31%), while 13 patients (48%) had progressive disease. Eight patients (25%) had a G 3-4 neutropenia, while G 3-4 anaemia was observed in 2 patients and thrombocytopenia in 1 patient. No extra-haematological G 3-4 toxicities were observed. A persistent G 2 hepatic toxicity led a patient to drop out from the study. Conclusion: In our phase II trial, CB in combination with R showed a moderate activity with safe administration on an outpatient basis.

  • Head and neck squamous cell carcinoma
  • carboplatin
  • raltitrexed

Footnotes

  • Received May 31, 2005.
  • Accepted September 6, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (6C)
Anticancer Research
Vol. 25, Issue 6C
1 Nov 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)
DOMENICO GALETTA, FRANCESCO GIOTTA, GERARDO ROSATI, VITTORIO GEBBIA, LUIGI MANZIONE, MAURIZIO DI BISCEGLIE, NICOLA BORSELLINO, GIUSEPPE COLUCCI
Anticancer Research Nov 2005, 25 (6C) 4445-4449;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)
DOMENICO GALETTA, FRANCESCO GIOTTA, GERARDO ROSATI, VITTORIO GEBBIA, LUIGI MANZIONE, MAURIZIO DI BISCEGLIE, NICOLA BORSELLINO, GIUSEPPE COLUCCI
Anticancer Research Nov 2005, 25 (6C) 4445-4449;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes
  • The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma
  • Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire